血管生成
癌症研究
免疫抑制
转移
肿瘤微环境
医学
放射治疗
巨噬细胞
细胞毒性T细胞
免疫疗法
化疗
免疫学
免疫系统
癌症
生物
肿瘤细胞
内科学
体外
生物化学
作者
Michele De Palma,Claire E. Lewis
出处
期刊:Cancer Cell
[Elsevier]
日期:2013-03-01
卷期号:23 (3): 277-286
被引量:969
标识
DOI:10.1016/j.ccr.2013.02.013
摘要
Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like angiogenesis, immunosuppression, invasion, and metastasis. Increasing studies have also shown that TAMs can either enhance or antagonize the antitumor efficacy of cytotoxic chemotherapy, cancer-cell targeting antibodies, and immunotherapeutic agents—depending on the type of treatment and tumor model. TAMs also drive reparative mechanisms in tumors after radiotherapy or treatment with vascular-targeting agents. Here, we discuss the biological significance and clinical implications of these findings, with an emphasis on novel approaches that effectively target TAMs to increase the efficacy of such therapies. Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like angiogenesis, immunosuppression, invasion, and metastasis. Increasing studies have also shown that TAMs can either enhance or antagonize the antitumor efficacy of cytotoxic chemotherapy, cancer-cell targeting antibodies, and immunotherapeutic agents—depending on the type of treatment and tumor model. TAMs also drive reparative mechanisms in tumors after radiotherapy or treatment with vascular-targeting agents. Here, we discuss the biological significance and clinical implications of these findings, with an emphasis on novel approaches that effectively target TAMs to increase the efficacy of such therapies. TAMs may either enhance or limit the efficacy of chemotherapy TAMs protect tumors from the effects of radiation and vascular-targeting agents TAMs enhance the activity of therapeutic antibodies via ADCC or ADCP Targeting or reprogramming TAMs may improve the efficacy of anticancer therapies
科研通智能强力驱动
Strongly Powered by AbleSci AI